Is a single nucleotide polymorphism a risk factor for lung cancer in the matrix metalloproteinase-2 promoter?

Our plain-English summary of Is a single nucleotide polymorphism a risk factor for lung cancer in the matrix metalloproteinase-2 promoter?, by B. Ayşegül, G.H. Veysi, M. Muzaffer, et al (Molecular Biology Reports, 2011).

The study

• Authors: B. Ayşegül, G.H. Veysi, M. Muzaffer, D. Irfan, A. Azra, K. Hulyam
• Journal: Molecular Biology Reports
• Published: 2011;38(3):1469-74
• Cited by: 15 articles, as counted by NIH iCite
• Read it: PubMed · Publisher

Abstract

We aimed to investigate the association of polymorphism frequencies of MMP-2 C1306T and MMP-2 plasma enzyme activity in lung cancer patients. In this study 300 genomic DNA (200 lung cancer patients + 100 no lung cancer) were analyzed. Polymorphisms were determined by using polymerase chain reaction-restriction fragment length polymorphism (RFLP) and electrophoresis. Plasma MMP-2 enzyme activity levels were measured by using ELISA. Sex, asbestos expose and smoking might be risk factors for lung cancer. The frequencies of C1306T genotypes in controls CC 65%, CT 32%, TT 3% and in patients CC 61%, CT 37%, TT2 % were found. It was determined that CC genotype frequency increase significantly in patients and controls. Plasma MMP-2 enzyme activity levels were increased in lung cancer patients according to controls. Finally, we claimed that determining of MMP-2 enzyme level can be used as a marker in lung cancer.

In plain English

This study, from Eskişehir Osmangazi University in Turkey, compared 200 patients diagnosed with lung cancer by bronchoscopy in 2005–2007 with 100 people without lung cancer. The authors tested blood for a genetic variant (C1306T) in the gene for an enzyme called MMP-2, and measured blood levels of that enzyme. Asbestos contact was recorded, though not the study's focus. It was recorded for 42 of 200 patients (21%) and 2 of 100 controls (2%), a statistically significant difference. The article does not describe that exposure. Smoking and COPD were also more common in patients. Genotype patterns did not differ significantly between groups: CC 61%, CT 37% and TT 2% in patients, against CC 65%, CT 32% and TT 3% in controls. Average enzyme level was significantly higher in patients (35.09 ng/ml) than controls (23.37 ng/ml); no statistically significant difference by genotype was found. The authors concluded that the variant was not a good indicator for their population. They suggested that enzyme level might be a marker of moderate sensitivity and low specificity. The article gives conflicting sensitivity and specificity figures.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Hospital-based comparison of lung cancer patients with a control group without lung cancer (case-control design), using genotyping and blood enzyme measurement
• Who was studied: 200 patients diagnosed with lung cancer by bronchoscopy at Eskişehir Osmangazi University, Turkey, in 2005–2007, and 100 control individuals without lung cancer
• Exposure: The main factors studied were the MMP-2 C1306T gene variant (CC, CT and TT genotypes) and plasma MMP-2 enzyme level. Asbestos contact, smoking and other characteristics were recorded as individual features. No fiber type, job or dose is given for asbestos.
• Main results:
  • Asbestos contact was more common in lung cancer patients than in controls (Table 2: 42 of 200 patients, 21%, versus 2 of 100 controls, 2%; chi-square 19.23, P less than 0.05)
  • Smoking (Table 2: 191 of 200 patients, 95%, versus 28 of 100 controls, 28%) and COPD (50 of 200 patients, 25%, versus 8 of 100 controls, 8%) were also statistically more common in patients
  • Genotype frequencies were CC 65%, CT 32%, TT 3% in controls and CC 61%, CT 37%, TT 2% in patients, with no statistically significant difference between the groups (chi-square 0.802, P greater than 0.05)
  • Average plasma MMP-2 enzyme level was statistically higher in all patients (35.09 plus or minus 0.76 ng/ml, n = 200) than in controls (23.37 plus or minus 0.63 ng/ml, n = 100), P less than 0.05
  • No statistically significant difference in enzyme level was found between genotypes, either in controls or in patients, including patient subgroups
  • ROC analysis set an enzyme cut-off of 23.65 ng/ml, with an area under the curve of 0.737 (95% CI 0.684–0.786). The text gives sensitivity 59% and specificity 79.5%, but Table 5 gives sensitivity 0.795 (95% CI 0.732–0.849) and specificity 0.59 (95% CI 0.487–0.687).
• The authors' conclusion: The authors concluded that the C1306T genotype was not a good indicator for their population. They concluded that measuring plasma MMP-2 enzyme activity might be a good indicator, at moderate sensitivity and low specificity, in surveillance studies of lung cancer.

Topics

The National Library of Medicine indexes this study under subjects our site covers: Lung cancer.

Medical terms in this study, explained in our Lexicon: Lung Cancer.

Related studies

• Heme oxygenase-1 promoter polymorphism is associated with risk of malignant mesothelioma — A. Murakami, Y. Fujimori, et al. (2012)
• Tumour necrosis factor-alpha gene polymorphisms in asbestos-induced diseases — S. Helmig, N. Aliahmadi, et al. (2010)
• Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study — C. Xue, N. Wu, et al. (2017)
• Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma — D. Štrbac, K. Goričar, et al. (2017)
• Methylation of MGMT in malignant pleural mesothelioma occurs in a subset of patients and is associated with the T allele of the rs16906252 MGMT promoter SNP — L.S. Kristensen, H.M. Nielsen, et al. (2011)
• Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma — S. Landi, F. Gemignani, et al. (2007)

Browse return to medical research.